Reappraisal of vitamin B6 therapy for West syndrome

Yuki Imai, Harumi Yoshinaga, Yumiko Ishizaki, Yoshiaki Watanabe, Yoko Ohtsuka

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Vitamin B6 (VB6) is used frequently as one of the first-choice drug for the treatment of West syndrome (WS) in Japan. We report 2 cases of symptomatic WS who had a good response to readministration of VB 6. Case 1 was a 3-year-old girl diagnosed as having severe hydroencephalus. She developed WS at the age of 9 months. She was treated with ACTH, but relapsed when she was 1 year old. Despite treatment with various conventional drugs and second ACTH therapy, her seizures were not suppressed. We reviewed past treatment records in another hospital, and found that VB 6 treatment was stopped because her EEG did not improve within a week. We then retried VB6 therapy when she was 3 years and 6 months old, and as a result she became seizure-free and hypsarrhythmia disappeared on EEG within a month. Case 2 was a boy with severe cerebral palsy who was diagnosed as having WS at the age of 9 months. His MRI revealed bilateral subdural hematoma. Treatment was started with VB6, and he became seizure-free within several days. But 7 days after starting VB6, treatment was stopped because of the side effects. VPA was started instead, but his EEG showed gradual worsening. Then, we added a smaller dose of VB 6 to VPA. His EEG improved dramatically, and his seizures have been controlled without any side effects. The present cases indicate the possible clinical usefulness of successful VB6 retrials even in older patients with severe organic lesions, by means of combined therapy with other drug, and alternative design of the dosing. However, we suspect there might be many cases in which me efficacy of VB6 therapy has not been properly assessed due to the short observation period and/or side effects.

Original languageEnglish
Pages (from-to)457-461
Number of pages5
JournalNo To Hattatsu
Volume41
Issue number6
Publication statusPublished - 2009

Fingerprint

Infantile Spasms
Vitamin B 6
Electroencephalography
Seizures
Therapeutics
Adrenocorticotropic Hormone
Subdural Hematoma
Drug Design
Cerebral Palsy
Pharmaceutical Preparations
Japan
Observation

ASJC Scopus subject areas

  • Clinical Neurology
  • Pediatrics, Perinatology, and Child Health

Cite this

Imai, Y., Yoshinaga, H., Ishizaki, Y., Watanabe, Y., & Ohtsuka, Y. (2009). Reappraisal of vitamin B6 therapy for West syndrome. No To Hattatsu, 41(6), 457-461.

Reappraisal of vitamin B6 therapy for West syndrome. / Imai, Yuki; Yoshinaga, Harumi; Ishizaki, Yumiko; Watanabe, Yoshiaki; Ohtsuka, Yoko.

In: No To Hattatsu, Vol. 41, No. 6, 2009, p. 457-461.

Research output: Contribution to journalArticle

Imai, Y, Yoshinaga, H, Ishizaki, Y, Watanabe, Y & Ohtsuka, Y 2009, 'Reappraisal of vitamin B6 therapy for West syndrome', No To Hattatsu, vol. 41, no. 6, pp. 457-461.
Imai Y, Yoshinaga H, Ishizaki Y, Watanabe Y, Ohtsuka Y. Reappraisal of vitamin B6 therapy for West syndrome. No To Hattatsu. 2009;41(6):457-461.
Imai, Yuki ; Yoshinaga, Harumi ; Ishizaki, Yumiko ; Watanabe, Yoshiaki ; Ohtsuka, Yoko. / Reappraisal of vitamin B6 therapy for West syndrome. In: No To Hattatsu. 2009 ; Vol. 41, No. 6. pp. 457-461.
@article{aa18a74875a9487abfdcf1d2b6211649,
title = "Reappraisal of vitamin B6 therapy for West syndrome",
abstract = "Vitamin B6 (VB6) is used frequently as one of the first-choice drug for the treatment of West syndrome (WS) in Japan. We report 2 cases of symptomatic WS who had a good response to readministration of VB 6. Case 1 was a 3-year-old girl diagnosed as having severe hydroencephalus. She developed WS at the age of 9 months. She was treated with ACTH, but relapsed when she was 1 year old. Despite treatment with various conventional drugs and second ACTH therapy, her seizures were not suppressed. We reviewed past treatment records in another hospital, and found that VB 6 treatment was stopped because her EEG did not improve within a week. We then retried VB6 therapy when she was 3 years and 6 months old, and as a result she became seizure-free and hypsarrhythmia disappeared on EEG within a month. Case 2 was a boy with severe cerebral palsy who was diagnosed as having WS at the age of 9 months. His MRI revealed bilateral subdural hematoma. Treatment was started with VB6, and he became seizure-free within several days. But 7 days after starting VB6, treatment was stopped because of the side effects. VPA was started instead, but his EEG showed gradual worsening. Then, we added a smaller dose of VB 6 to VPA. His EEG improved dramatically, and his seizures have been controlled without any side effects. The present cases indicate the possible clinical usefulness of successful VB6 retrials even in older patients with severe organic lesions, by means of combined therapy with other drug, and alternative design of the dosing. However, we suspect there might be many cases in which me efficacy of VB6 therapy has not been properly assessed due to the short observation period and/or side effects.",
author = "Yuki Imai and Harumi Yoshinaga and Yumiko Ishizaki and Yoshiaki Watanabe and Yoko Ohtsuka",
year = "2009",
language = "English",
volume = "41",
pages = "457--461",
journal = "No To Hattatsu",
issn = "0029-0831",
publisher = "Japanese Society of Child Neurology",
number = "6",

}

TY - JOUR

T1 - Reappraisal of vitamin B6 therapy for West syndrome

AU - Imai, Yuki

AU - Yoshinaga, Harumi

AU - Ishizaki, Yumiko

AU - Watanabe, Yoshiaki

AU - Ohtsuka, Yoko

PY - 2009

Y1 - 2009

N2 - Vitamin B6 (VB6) is used frequently as one of the first-choice drug for the treatment of West syndrome (WS) in Japan. We report 2 cases of symptomatic WS who had a good response to readministration of VB 6. Case 1 was a 3-year-old girl diagnosed as having severe hydroencephalus. She developed WS at the age of 9 months. She was treated with ACTH, but relapsed when she was 1 year old. Despite treatment with various conventional drugs and second ACTH therapy, her seizures were not suppressed. We reviewed past treatment records in another hospital, and found that VB 6 treatment was stopped because her EEG did not improve within a week. We then retried VB6 therapy when she was 3 years and 6 months old, and as a result she became seizure-free and hypsarrhythmia disappeared on EEG within a month. Case 2 was a boy with severe cerebral palsy who was diagnosed as having WS at the age of 9 months. His MRI revealed bilateral subdural hematoma. Treatment was started with VB6, and he became seizure-free within several days. But 7 days after starting VB6, treatment was stopped because of the side effects. VPA was started instead, but his EEG showed gradual worsening. Then, we added a smaller dose of VB 6 to VPA. His EEG improved dramatically, and his seizures have been controlled without any side effects. The present cases indicate the possible clinical usefulness of successful VB6 retrials even in older patients with severe organic lesions, by means of combined therapy with other drug, and alternative design of the dosing. However, we suspect there might be many cases in which me efficacy of VB6 therapy has not been properly assessed due to the short observation period and/or side effects.

AB - Vitamin B6 (VB6) is used frequently as one of the first-choice drug for the treatment of West syndrome (WS) in Japan. We report 2 cases of symptomatic WS who had a good response to readministration of VB 6. Case 1 was a 3-year-old girl diagnosed as having severe hydroencephalus. She developed WS at the age of 9 months. She was treated with ACTH, but relapsed when she was 1 year old. Despite treatment with various conventional drugs and second ACTH therapy, her seizures were not suppressed. We reviewed past treatment records in another hospital, and found that VB 6 treatment was stopped because her EEG did not improve within a week. We then retried VB6 therapy when she was 3 years and 6 months old, and as a result she became seizure-free and hypsarrhythmia disappeared on EEG within a month. Case 2 was a boy with severe cerebral palsy who was diagnosed as having WS at the age of 9 months. His MRI revealed bilateral subdural hematoma. Treatment was started with VB6, and he became seizure-free within several days. But 7 days after starting VB6, treatment was stopped because of the side effects. VPA was started instead, but his EEG showed gradual worsening. Then, we added a smaller dose of VB 6 to VPA. His EEG improved dramatically, and his seizures have been controlled without any side effects. The present cases indicate the possible clinical usefulness of successful VB6 retrials even in older patients with severe organic lesions, by means of combined therapy with other drug, and alternative design of the dosing. However, we suspect there might be many cases in which me efficacy of VB6 therapy has not been properly assessed due to the short observation period and/or side effects.

UR - http://www.scopus.com/inward/record.url?scp=70549095827&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70549095827&partnerID=8YFLogxK

M3 - Article

C2 - 19928546

AN - SCOPUS:70549095827

VL - 41

SP - 457

EP - 461

JO - No To Hattatsu

JF - No To Hattatsu

SN - 0029-0831

IS - 6

ER -